BeOne Medicines Ltd. American Depositary Shares
ONC
$301.88
-2.29%
BeOne Medicines Ltd. (formerly BeiGene) is a commercial-stage biotechnology company focused on developing and commercializing oncology therapeutics, with its lead product Brukinsa treating multiple forms of Non-Hodgkin lymphoma and leukemia. The company operates globally, conducting drug discovery, clinical trials, and manufacturing independently, positioning itself as a key player in the targeted cancer therapy space against giants like AbbVie and AstraZeneca. Investor attention is currently centered on BeOne's transition to profitability, driven by strong Brukinsa sales (74% of revenue) and a robust pipeline of over 50 clinical-stage assets, while the recent name change and continued revenue growth fuel debate about its long-term competitive positioning and margin expansion potential.…
ONC
BeOne Medicines Ltd. American Depositary Shares
$301.88
Investment Opinion: Should I buy ONC Today?
Rating: Buy. Thesis: BeOne Medicines is a high-growth biotech that has crossed the profitability threshold, with accelerating revenue and strong margins, but valuation requires careful entry. The analyst consensus is bullish with 14 of 15 analysts rating Buy, and the implied average target of ~$600 suggests over 100% upside from $297.65. Supporting evidence: (1) Revenue growth of 32.8% YoY with sequential acceleration; (2) Gross margin of 85.3% TTM, well above biotech averages; (3) Positive net income of $66.5M in Q4 2025, a $218M swing from a year ago; (4) Forward P/E of 30.64x, which, while a premium to the industry 22x, is justified by the 32.8% growth rate and improving operating leverage. Risks: The biggest risk is that growth decelerates below 20%, compressing the forward multiple; a pipeline failure could also trigger a re-rating. This Buy would downgrade to Hold if forward P/E expands above 35x without commensurate growth acceleration, or if Brukinsa market share declines. The stock is fairly valued relative to its growth rate (PEG <1 on forward estimates) but overvalued on trailing earnings; investors should view it as a growth-at-a-reasonable-price (GARP) opportunity.
Sign up to view all
ONC 12-Month Price Forecast
The AI assessment is bullish with medium confidence. BeOne's fundamental inflection—positive net income and free cash flow—is a powerful catalyst that should support multiple expansion over the next 12 months. The 32.8% revenue growth rate is exceptional and justifies the forward P/E premium. However, the high trailing multiple and concentration risk temper conviction. Key developments to watch: sustained revenue growth above 25%, margin expansion, and pipeline progress. An upgrade to high confidence would require two consecutive quarters of accelerating growth and margin improvement; a downgrade would follow a growth deceleration below 20% or a major competitive setback.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BeOne Medicines Ltd. American Depositary Shares's 12-month outlook, with a consensus price target around $392.44 and implied upside of +30.0% versus the current price.
Average Target
$392.44
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$242 - $392
Analyst target range
The stock is covered by 15 analysts, with a consensus leaning bullish. Recent ratings include multiple Buy/Overweight ratings from firms like Truist, Guggenheim, RBC Capital, Barclays, and Citigroup, though Jefferies downgraded to Hold in March 2026. The average target price is not explicitly provided, but based on estimated EPS of $19.59 and a forward P/E of 30.64x, the implied target is approximately $600 (19.59 * 30.64), suggesting over 100% upside from the current price of $297.65. However, this is a rough calculation; actual analyst targets may vary. The high EPS estimate of $20.85 implies a target of ~$639, while the low of $18.64 implies ~$571. The wide range reflects uncertainty around pipeline success and market share. The recent downgrade by Jefferies to Hold indicates some caution, but the overall sentiment remains positive. The implied upside from the average target is substantial, but investors should consider the high valuation and execution risks.
Drowning in data?
Find the real signal!
Bulls vs Bears: ONC Investment Factors
BeOne Medicines presents a compelling turnaround story with accelerating revenue growth (32.8% YoY), achieved profitability, and strong margins (85.3% gross). The bull case is anchored by the transition to positive net income and free cash flow, supported by a healthy balance sheet. However, the bear case highlights extreme valuation (trailing P/E 182.85x), heavy reliance on Brukinsa (74% of revenue), and a forward P/E premium of 39% over industry peers. The single most important tension is whether the company can sustain its growth trajectory and margin expansion to justify the forward multiple; if revenue growth decelerates or competition erodes Brukinsa market share, the stock could face significant de-rating. Currently, the bull case has stronger evidence given the fundamental inflection, but valuation risk tempers enthusiasm.
Bullish
- Revenue Growth Accelerating: Revenue grew 32.8% YoY in Q4 2025 to $1.498B, with sequential acceleration from $1.117B in Q1 to $1.498B in Q4, indicating strong commercial execution for Brukinsa.
- Achieved Profitability: Net income turned positive at $66.5M in Q4 2025 vs -$151.9M a year ago, and TTM net income is $382.5M, marking a pivotal transition to sustainable profitability.
- Strong Gross Margin: Gross margin reached 85.3% TTM, with Q4 2025 at 90.5%, reflecting high-value oncology drugs and operating leverage as scale increases.
- Healthy Balance Sheet: Current ratio of 3.41 and debt-to-equity of 0.25 indicate ample liquidity and conservative leverage, reducing financial distress risk.
Bearish
- High Trailing P/E: Trailing P/E of 182.85x is extremely elevated, reflecting the recent swing to profitability; any earnings miss could trigger severe multiple compression.
- Revenue Concentration Risk: Brukinsa accounts for 74% of total revenue, making the company highly dependent on a single drug facing competition from AbbVie and AstraZeneca.
- Forward P/E Premium: Forward P/E of 30.64x is 39% above the biotech industry average of ~22x, requiring sustained high growth to justify the premium.
- Recent Price Decline: Stock is down 22.7% from its 52-week high of $385.22, and 3-month relative strength vs SPY is -17.79%, indicating persistent underperformance.
ONC Technical Analysis
The stock is in a broad uptrend over the past year, with a 1-year price change of +21.8%, but has experienced significant volatility. Currently trading at $297.65, the stock sits at 77% of its 52-week range (low $240, high $385.22), indicating it is well off the highs but above the lows, suggesting a consolidation phase after a sharp decline from the peak. The 52-week high of $385.22 represents a key resistance level, while the low of $240 provides support. The beta of 0.494 indicates the stock is less volatile than the market, which is unusual for a biotech and may reflect its large-cap status or specific investor base. Over the past 1 month, the stock has gained 8.36%, while over 3 months it has declined 4.23%, creating a divergence with the 1-year uptrend. This short-term recovery from the June lows (around $260) suggests a potential reversal or mean reversion, but the 3-month negative performance indicates lingering bearish pressure. The 1-month relative strength vs. SPY is +9.61%, showing recent outperformance, but the 3-month relative strength is -17.79%, highlighting a longer-term underperformance. The 52-week high of $385.22 and low of $240 define the trading range. A breakout above $385 would signal a resumption of the uptrend and could target new highs, while a breakdown below $240 would indicate a bearish reversal and potential further downside. With a beta of 0.494, the stock is less sensitive to market moves, meaning its volatility is driven more by company-specific factors than broad market swings, which is important for risk management.
Beta
0.49
0.49x market volatility
Max Drawdown
-31.1%
Largest decline past year
52-Week Range
$249-$385
Price range past year
Annual Return
+23.5%
Cumulative gain past year
| Period | ONC Return | S&P 500 |
|---|---|---|
| 1m | +11.5% | +0.8% |
| 3m | -3.7% | +9.6% |
| 6m | -10.7% | +7.4% |
| 1y | +23.5% | +20.2% |
| ytd | -2.9% | +9.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ONC Fundamental Analysis
Revenue has been growing strongly, with the most recent quarter (Q4 2025) reporting $1.498 billion, up 32.8% year-over-year. The multi-quarter trend shows accelerating growth: Q1 2025 revenue was $1.117 billion, Q2 $1.315 billion, Q3 $1.412 billion, and Q4 $1.498 billion, indicating a consistent upward trajectory. Product revenue of $1.902 billion (from segments) dominates, with collaboration revenue of $39 million, highlighting Brukinsa's central role. The company has achieved profitability, with net income of $66.5 million in Q4 2025, compared to a net loss of $151.9 million in Q4 2024, marking a significant turnaround. Gross margin is strong at 85.3% (trailing twelve months), and operating margin improved to 12.4% in Q4 2025 from negative levels a year ago, reflecting operating leverage. The balance sheet is healthy, with a current ratio of 3.41 and low debt-to-equity of 0.25, indicating ample liquidity and conservative leverage. Free cash flow was $131.3 million in Q4 2025, positive for the second consecutive quarter, and trailing twelve-month FCF is $613.2 million, suggesting the company is now self-funding growth. ROE is 6.8%, still modest but improving from negative levels, and the company has no dividend, reinvesting all earnings into growth.
Quarterly Revenue
$1.5B
2025-12
Revenue YoY Growth
+32.84%
YoY Comparison
Gross Margin
90.49%
Latest Quarter
Free Cash Flow
$613191000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ONC Overvalued?
Since net income is positive (TTM net income of $382.5 million), the primary valuation metric is the P/E ratio. The trailing P/E is 182.85x, while the forward P/E is 30.64x, implying the market expects significant earnings growth in the coming year. The wide gap between trailing and forward P/E reflects the recent swing to profitability and anticipated acceleration. Compared to the biotechnology industry average P/E of around 22x (based on sector data), BeOne's forward P/E of 30.64x represents a 39% premium, which may be justified by its strong revenue growth (32.8% YoY) and improving margins. Historically, the stock's P/E has ranged from negative (when unprofitable) to over 200x, so the current forward multiple is below its historical highs but still elevated. The P/S ratio of 9.92x is also high relative to the industry average of about 5x, but this is common for high-growth biotechs. The PEG ratio is negative (-1.77) due to negative earnings growth in the past, but forward estimates suggest a PEG below 1, indicating potential undervaluation relative to growth.
PE
182.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -4x~720x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
80.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is valuation vulnerability—trailing P/E of 182.85x leaves no room for error; any earnings disappointment could trigger a sharp contraction. While the company has low debt (D/E 0.25), the heavy reliance on Brukinsa (74% of revenue) creates concentration risk if competition from AbbVie or AstraZeneca intensifies. Operating margin improved to 12.4% in Q4 2025 but remains thin relative to the multiple, and R&D spending of $615M per quarter pressures near-term profitability. Market & Competitive Risks: The stock's beta of 0.494 suggests low market correlation, but its 3-month relative strength of -17.79% vs SPY indicates sector-specific headwinds. The forward P/E of 30.64x is a 39% premium to the biotech industry average, making it susceptible to multiple compression if growth slows. Competitive threats from larger players with deeper pipelines could erode Brukinsa's market share, and the recent Jefferies downgrade to Hold signals some analyst caution. Worst-Case Scenario: A combination of Brukinsa sales deceleration, a pipeline setback, and broader biotech sector rotation could drive the stock to its 52-week low of $240, representing a 19.4% decline from the current price of $297.65. In a severe scenario, if profitability reverses or a major trial fails, the stock could revisit historical lows near $200, implying a 32.8% loss from current levels.
FAQ
The key risks are: (1) Revenue concentration—Brukinsa accounts for 74% of revenue, making the company vulnerable to competition from AbbVie and AstraZeneca; (2) Valuation risk—trailing P/E of 182.85x leaves no margin for error, and a growth deceleration could trigger a severe de-rating; (3) Pipeline risk—with over 50 clinical-stage assets and R&D spending of $615M per quarter, a late-stage trial failure could damage sentiment; (4) Macro risk—while beta is low at 0.494, the stock is still sensitive to biotech sector rotations and interest rate changes. The most severe risk is a combination of competitive pressure and pipeline setback, which could drive the stock to the 52-week low of $240 or below.
The 12-month forecast is bullish with a base case target range of $300-$450 (50% probability), a bull case of $450-$600 (30% probability), and a bear case of $240-$300 (20% probability). The base case assumes 25-30% revenue growth and gradual margin expansion, keeping the forward P/E around 30x. The bull case requires accelerating growth above 35% and positive pipeline catalysts. The bear case involves competitive erosion or pipeline failure. The most likely scenario is the base case, with the stock trading in a range as fundamentals improve but valuation limits upside. Key catalysts include the next earnings report and pipeline data readouts.
ONC is overvalued on trailing earnings (P/E 182.85x) but fairly valued on forward earnings (P/E 30.64x) relative to its 32.8% revenue growth rate. The forward P/E is a 39% premium to the biotech industry average of 22x, which is justified by the company's growth trajectory and improving margins. The P/S ratio of 9.92x is also high versus the industry average of ~5x, but common for high-growth biotechs. The PEG ratio is negative due to past losses, but forward estimates imply a PEG below 1, suggesting undervaluation relative to growth. Overall, the market is pricing in continued strong execution, and any slowdown could lead to multiple compression.
ONC is a good buy for growth investors willing to accept elevated valuation in exchange for high revenue growth (32.8% YoY) and a recent profitability inflection. The analyst consensus is bullish with an implied average target of ~$600, offering over 100% upside from $297.65. However, the trailing P/E of 182.85x means any earnings miss could lead to sharp declines. The stock is best suited for those with a long-term horizon who can withstand volatility; for short-term traders, the high beta and recent price swings (22.7% off the 52-week high) present significant risk. Overall, it is a buy on dips, but investors should size positions carefully.
ONC is more suitable for long-term investment (3-5 years) given its growth stage and volatility. The stock has a beta of 0.494, indicating lower market correlation, but its 3-month decline of 4.2% and 22.7% drop from the 52-week high show significant company-specific risk. Short-term traders may find opportunities around earnings events, but the high trailing P/E and concentration risk make it a risky short-term hold. The company does not pay a dividend, so returns depend entirely on price appreciation. A minimum holding period of 2-3 years is recommended to allow the growth story to play out and valuation to normalize.
